More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the ...

Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...

Nov. 13, 2024 /PRNewswire/ -- TileDB, the database designed for scientific discovery, announced today it is now utilized by 50% of the top 20 global pharmaceutical companies, including industry giant ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...

Nov. 13, 2024 /PRNewswire/ — TileDB, the database designed for scientific discovery, announced today it is now utilized by 50% of the top 20 global pharmaceutical companies, including industry giant ...

The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...

STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...

Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

(MENAFN- GlobeNewsWire - Nasdaq) Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of health & Human Services, et al. Washington, D.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Today, ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...